fda ban tirzepatide Compounded Still on Market Despite FDA ban on compounded tirzepatide:

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Unless you have a true biotin deficiency which is uncommon but can occur with chronic alcohol use, pregnancy, certain gastrointestinal disorders, or long-term anticonvulsant therapy biotin supplements: Do not improve hair growth Do not prevent telogen effluvium Can falsely alter important lab tests (including thyroid & cardiac troponin levels) Multiple dermatology reviews and placebo-controlled trials show no benefit for biotin supplementation in people with normal biotin levels

For patients with pre-existing osteopenia or osteoporosis, a baseline DXA may change the risk-benefit calculation of GLP-1 therapy entirely

Tirzepatide is a prescription medication approved by the FDA for the treatment of type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related comorbidities (marketed as Zepbound)

Additionally, the appetite-suppressing effects of GLP-1 medications can partially attenuate over time as receptors adjust to sustained stimulation

When our friend tirzepatide received its FDA approval for weight loss, and simultaneously telehealth platforms increased prescribing of GLP-1s for patients, we saw this shortage situation explode